Ovation Science Inc. is a developer of cannabis-infused topicals, backed by patents and science and generating royalties through an out-licensing business model in the United States and international markets
Whitefish, Montana–(Newsfile Corp. – March 16, 2021) – CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Ovation Science Inc. (CSE: OVAT) (OTCQB: OVATF) to its growing client roster.
Ovation Science Inc.
To view an enhanced version of this graphic, please visit:
CFN Media will leverage its proprietary digital content platform and extensive distribution network-including its flagship CannabisFN website-to attract targeted retail, accredited and institutional investors to Ovation Science Inc.
“We are excited to be working with Ovation Science as it ramps up the commercialization of its cannabis-infused topicals,” said CFN Media President Frank Lane. “Topical cannabis products appeal to traditional cannabis users as well as non-traditional users exploring cannabis’ medicinal properties for the first time, and represent one of the industry’s fastest growing segments.”
Ovation Science has developed a line of cannabis-infused topical products backed by over 20 years of research and development. Powered by its Invisicare® drug delivery technology, the company offers topicals that remain on the skin and transdermal creams that deliver CBD and THC through the skin and into the bloodstream.
“We are excited to be working with CFN Media as they have an extensive network that targets the cannabis investment space,” said Terry Howlett, President & CEO of Ovation Science Inc. “With our recent listing on the OTCQB, and the positive changes taking place in the cannabis industry in the USA, we engaged CFN Media as our partner to create greater awareness of Ovation’s products and achievements to their broad investment audience.”
Topical cannabinoids have become increasingly popular over the past few years. Consumers have embraced the medicinal side of these products including their anti-inflammatory, anti-anxiety properties, even anti-aging benefits.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC cannabis formulations including ARLO CBD Beauty and InVibe® MD (“health & wellness” line), and secondly, its unique DermSafe® hand sanitizer; all made with its patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas.
Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees along with revenue from its own product sales.
Ovation has offices in Vancouver, BC, Canada and Las Vegas, Nevada, USA.
Ovation trades on the CSE under the symbol OVAT and in the USA on OTC Markets under the symbol OVATF.
Visit our website www.ovationscience.com for more information.
About CFN Enterprises Inc.
CFN Enterprises Inc. (OTCQB: CNFN) is a digital media and ecommerce company focused on advancing businesses and brands in highly regulated emerging industries across the globe. CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives. Learn more at www.cfnenterprisesinc.com.
CFN Enterprises Inc. Media Contact:
CFN Enterprises Inc.
+001 (833) 420-CNFN
Use of Forward-looking Statements
This press release may contain forward-looking statements from CFN Enterprises Inc. within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when CFN Enterprises Inc. describes Ovation Science Inc.’s business, and uses other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, CFN Enterprises Inc. is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of CFN Enterprises Inc. only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of CFN Enterprises Inc. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, CFN Enterprises Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting CFN Enterprises Inc., reference is made to CFN Enterprises Inc.’s reports filed from time to time with the Securities and Exchange Commission.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77396